Trial Profile

A Phase 1/2, Open-Label, Dose-Escalation and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-992 in Subjects With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 29 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OBI 992 (Primary)
Indications Gastric cancer; Non-small cell lung cancer; Small cell lung cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use

22 Apr 2025 According to an OBI Pharma media release, data from this study will be presented at the American Association of Cancer Research (AACR) Annual Meeting from April 25 to 30, 2025 in Chicago, Illinois (USA).
12 Jun 2024 According to an OBI Pharma media release, Leia Tsimberidou MD, of MD Anderson Cancer Center in Houston, TX. USA is the lead investigator for the study.
12 Jun 2024 Status changed from planning to recruiting, according to an OBI Pharma media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com